This is a preview of subscription content, log in via an institution to check access.
Reference
Barrington DA, et al. Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. Gynecologic Oncology : 17 Jun 2021. Available from: URL: http://doi.org/10.1016/j.ygyno.2021.06.014
Rights and permissions
About this article
Cite this article
Lenvatinib + pembrolizumab is not cost effective for recurrent MSS endometrial cancer. PharmacoEcon Outcomes News 882, 17 (2021). https://doi.org/10.1007/s40274-021-7851-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7851-4